KCS Wealth Advisory purchased a new position in shares of Novartis AG (NYSE:NVS) during the fourth quarter, HoldingsChannel reports. The firm purchased 5,423 shares of the company’s stock, valued at approximately $455,000.
Other hedge funds have also modified their holdings of the company. WFG Advisors LP boosted its position in Novartis by 38.1% during the second quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after purchasing an additional 337 shares in the last quarter. Wealthcare Advisory Partners LLC purchased a new position in Novartis during the third quarter worth approximately $106,000. Cable Hill Partners LLC boosted its position in Novartis by 588.8% during the third quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock worth $112,000 after purchasing an additional 1,107 shares in the last quarter. Harding Loevner LP purchased a new position in Novartis during the second quarter worth approximately $146,000. Finally, Sawyer & Company Inc purchased a new position in Novartis during the fourth quarter worth approximately $183,000. Institutional investors own 10.85% of the company’s stock.
Novartis AG (NYSE NVS) opened at $86.65 on Friday. The firm has a market capitalization of $202,660.52, a P/E ratio of 18.04, a PEG ratio of 2.35 and a beta of 0.73. Novartis AG has a 1 year low of $69.53 and a 1 year high of $86.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81.
A number of equities analysts have issued reports on NVS shares. Zacks Investment Research upgraded Novartis from a “hold” rating to a “buy” rating and set a $96.00 price target on the stock in a research report on Tuesday, September 19th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a research report on Tuesday, September 26th. Leerink Swann raised their target price on Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Barclays downgraded Novartis from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, October 25th. Finally, Bank of America downgraded Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th. Five analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $85.32.
TRADEMARK VIOLATION WARNING: “5,423 Shares in Novartis AG (NVS) Acquired by KCS Wealth Advisory” was first published by BBNS and is the property of of BBNS. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://baseballnewssource.com/markets/5423-shares-in-novartis-ag-nvs-acquired-by-kcs-wealth-advisory/1827855.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with our FREE daily email newsletter.